Market Tracker

07/26 6:06am ET

Fibrocell Science Inc (NASDAQ:FCSC)

1.04
Delayed Data
As of Jul 25
 -0.03 / -2.80%
Today’s Change
0.91
Today|||52-Week Range
7.60
-77.14%
Year-to-Date
Zafgen Halts Development of Beloranib, to Cut Jobs by ~34%
Jul 20 / Zacks.com - Paid Partner Content
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Jul 18 / Zacks.com - Paid Partner Content
Celgene (CELG), Jounce Strike Immunotherapy Collaboration
Jul 20 / Zacks.com - Paid Partner Content
TrovaGene Inks Partnership with USC Norris Cancer Center
Jul 13 / Zacks.com - Paid Partner Content
Bristol-Myers' Opdivo Label Expansion Under U.S., EU Review
Jul 19 / Zacks.com - Paid Partner Content
Bayer Expands Drug Discovery Collaboration with X-Chem
Jul 13 / Zacks.com - Paid Partner Content
AstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint
Jul 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close1.07
Today’s open1.08
Day’s range1.03 - 1.08
Volume151,432
Average volume (3 months)336,951
Market cap$47.0M
Dividend yield--
Data as of 07/25/2016

Growth & Valuation

Earnings growth (last year)-22.23%
Earnings growth (this year)+38.82%
Earnings growth (next 5 years)+15.00%
Revenue growth (last year)+173.33%
P/E ratioNM
Price/Sales391.66
Price/Book3.31

Competitors

 Today’s
change
Today’s
% change
GLMDGalmed Pharmaceutica...+0.08+1.90%
CNATConatus Pharmaceutic...+0.08+3.64%
MEIPMEI Pharma Inc+0.03+2.19%
CASICASI Pharmaceuticals...+0.02+1.79%
Data as of 07/25/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$0.17
Annual revenue (last year)$492.0K
Annual profit (last year)-$34.5M
Net profit margin-7,002.64%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
David M. Pernock
CFO, Treasurer &
Senior Vice President
Keith Alan Goldan
Corporate headquarters
Exton, Pennsylvania

Forecasts